Stockwinners Market Radar for January 25, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:11 EST Penumbra director sells $5.0M in common stock - In a regulatory filing, Penumbra disclosed that its director Arani Bose sold 20K shares of common stock on January 3rd in a total transaction size of $5.0M.

20:06 EST Allegro MicroSystems to open new R&D center in Dallas area - Allegro MicroSystem announces plans to open a new U.S.-based office located in Richardson, Texas. The company's newest innovation and design center will serve as a hub for Allegro's Sensors and Power Integrated Circuits research and development efforts, while furthering the company's mission to develop semiconductor chips that support a safer and more sustainable future.

19:27 EST Medtronic recommends rejection of below-market mini-tender by TRC Capital - The company states: "Medtronic recently became aware that TRC Capital Investment Corporation has made an unsolicited mini-tender offer to purchase up to 1,500,000 Medtronic ordinary shares, representing approximately 0.1% of the company's outstanding ordinary shares. TRC's offer price of $77.25 per share in cash is approximately 4.5% lower than the $80.91 closing price of Medtronic ordinary shares on January 20, 2023, the last closing price prior to commencement of the offer. Medtronic does not recommend or endorse TRC's unsolicited below-market mini-tender offer. Further, because the offer is at a price significantly below the current market price of Medtronic ordinary shares, Medtronic recommends that shareholders not tender their shares. Medtronic is not affiliated or associated with TRC, its mini-tender offer, or the mini-tender offer documentation."

19:12 EST Tesla extends afterhours gains, up over 5% at $152.45 - Shares of Tesla are now up 5.5% or $8.02 at $152.45, extending its post-earnings gains following the completion of its Q4 conference call. At after-hours levels, Tesla is trading at the highest level since December 15th.

18:28 EST Tesla CEO says Dojo AI to be competitive with Nvidia at end of 2023 - Says "We think Dojo will be competitive with the NVIDIA H1 at the end of this year and then hopefully surpass it next year."

18:24 EST Levi Strauss CEO: Fundamentally, our strategies are working - In an interview on CNBC's Mad Money, Chip Bergh said doubling down on the direct to consumer business is driving growth. It's now 39% of revenues, with a goal of 55%. The company has good momentum and he's "really optimistic" about 2023. The 501 brand has been a great driver of growth, he noted. Bergh sees tremendous opportunity to "premiumize" the U.S. He said once the board says so, he will step aside as CEO.

18:12 EST Tesla's Musk says probably will have 'difficult recession this year' - Says expect Cybertruck production to start this summer.

18:00 EST Reed's revises effective date for reverse stock split to January 27 - Reed's, Inc. announced that due to unanticipated delays in processing outside the company's control, the previously announced reverse stock split, which was to be effective with the open of The Nasdaq Stock Market on January 26, 2023, will instead take effect with the open of the market on Friday, January 27, 2023. The company will trade on a post-split basis under its current trading symbol "REED". However, upon implementation of the reverse split, the company's common stock will begin trading under new CUSIP 758338305. Upon implementation of the reverse stock split, every 50 shares of the company's issued and outstanding common stock will automatically convert into one share of common stock without any change to the par value of $0.0001 per share and the amount of common stock outstanding will be reduced from approximately 126 million shares to approximately 2.5 million shares. Proportional adjustments will be made to the number of shares of common stock issuable upon exercise of Reed's outstanding stock options and warrants, as well as the applicable exercise price.

17:56 EST Tesla's Musk says 2022 operating margin of 17% highest among any volume carmaker - Says 2022 $12.5B in net income and $7.5B in free cash flow were record high despite "an incredibly challenging year due to forced shutdowns, very high interest rates and many delivery challenges." Comments taken from Q4 earnings conference call.

17:47 EST TransMedics CEO Hassanein sells $801K in company shares - CEO of TransMedics Group Waleed Hassanein sold 12,362 shares of company stock at $65.42 per share on January 23, for a total transaction amount of $808,664.

17:35 EST Textron awarded $113.11M Navy contract - Textron was awarded a $113.11M firm-fixed-price contract to provide for the production and delivery of 10 Multi-Engine Training System aircraft, initial spares, peculiar support equipment, instructor pilot training, and maintenance personnel training to provide intermediate and advanced training for accession into P-8, EP-3, KC-130, E-6, E-2, CMV-22 and MV-22 aircraft in support of the mission of Chief Naval Air Training for the Navy. Work is expected to be completed in June 2024. Fiscal 2023 aircraft procurement funds in the amount of $113.11M will be obligated at the time if award, none of which will expire at the end of the current fiscal year. This contract was competitively procured via an electronic request for proposal; one offer was received. The Naval Air Systems Command is the contracting activity.

17:22 EST Seagate says business environment 'tough' - Says seeing some signs of market improvement. Says expects conditions to gradually improve over next several quarters. Expects stronger revenue, profitability in 2H23. Expects CapEx to trend lower in 2H23. Says cash flow sufficient to support dividend. Comments taken from Q2 earnings conference call.

17:19 EST NJ BPU okays IIF's acquisition of SJI, SJI will cease to be listed on Feb. 1 - South Jersey Industries and the Infrastructure Investments Fund, a private investment vehicle focused on investing in critical infrastructure assets, announced that the New Jersey Board of Public Utilities ,NJ BPU, has unanimously approved IIF's proposed acquisition of SJI. Under the terms of the NJ BPU approval, SJI has made the following commitments, among others:$75 million in financial benefits for Elizabethtown Gas and South Jersey Gas customers including, a rate credit to all customers and bill relief for certain accounts in arrears due to the COVID-19 pandemic. SJI and IIF issued the following statement: "We are pleased that the NJ BPU recognizes the significant benefits this partnership presents for the communities in which SJI operates. The NJ BPU's approval marks the final regulatory approval needed to complete the transaction, which we expect to occur on February 1 . As a result of the transaction, shares of common stock, $1.25 par value per share, of SJI will cease to be listed for trading on the New York Stock Exchange . In connection with the transaction, SJI also has provided notice to NYSE that it is voluntarily delisting its 5.625% Junior Subordinated Notes due 2079 and its Corporate Units from the NYSE. A Form 25 with respect to the delisting will be filed on or about February 6, 2023. The last day that common stock is traded on the NYSE, which is expected to be February 1.

17:17 EST DoubleVerify to replace Meridian Bioscience in S&P 600 at open on 1/31 - SD Biosensor is acquiring Meridian Bioscience in a deal expected to be completed soon pending final conditions.

17:03 EST SAP selected by Lockheed Martin for 1LMX program solution - Lockheed Martin (LMT) and SAP (NSAP) expanded their strategic relationship to transform the mission-critical business systems that power Lockheed Martin's OneLM Transformation Program - 1LMX -. 1LMX is the business and digital transformation effort that aims to enhance the speed, agility, insights and competitiveness of Lockheed Martin by leveraging data as a strategic asset, enabling a model-based enterprise that spans the full product value chain, and streamlining systems and processes. Lockheed Martin is leveraging the RISE with SAP solution to expand its enterprise cloud capabilities and introduce the tools needed to implement core business processes in managed FedRAMP-compliant cloud environments through the 1LMX initiative. In addition, SAP Business Technology Platform will provide Lockheed Martin with an innovation platform on which to develop emerging technologies.

16:51 EST Covenant Logistics sees 2023 CapEx $75M-$85M - CapEx guidance includes a range of $87M-$97M for revenue generating equipment offset by cash proceeds on the sale of a terminal of approximately $12M, net of transaction costs.

16:44 EST Ocuphire craters 31% after trial evaluating oral APX3330 fails to meet endpoint - Shares of Ocuphire are down 31% or $1.15 per share to $2.61 in after-market trading after reporting ZETA-1 Phase 2 trial evaluating oral APX3330 for the treatment of diabetic retinopathy or DR did not meet the primary endpoint.

16:42 EST Unitil raises quarterly dividend to 40.5c per share - Unitil announced that its board of directors raised the quarterly dividend on the company's common stock to 40.5c per share. Also, the board declared the first quarter common stock dividend of 40.5c per share, payable February 28 to shareholders of record on February 14.

16:41 EST Wolfspeed falls 6% to $76.80 after Q2 earnings and guidance

16:37 EST GasLog Partners receives $7.70 per unit buyout offer from GasLog - GasLog Partners announced that its board of directors received an unsolicited non-binding proposal from GasLog to acquire all of the outstanding common units representing limited partner interests of the partnership not already beneficially owned by GasLog. In connection with the proposed transaction, each common unit would receive overall value of $7.70 per common unit in cash, consisting in part of a special distribution by the partnership of $2.33 per common unit in cash to be distributed to the partnership's unitholders immediately prior to the closing of the proposed transaction and the remainder to be paid by GasLog as merger consideration at the closing of the proposed transaction. The Partnership's board of directors has authorized its conflicts committee, consisting only of non-GasLog affiliated directors, to retain advisors and to review, evaluate, negotiate and accept or reject the proposed transaction. GasLog's proposal is non-binding and is subject to the negotiation and execution of mutually acceptable definitive documentation. There can be no assurance that any definitive documentation will be executed or that any transaction will materialize.

16:36 EST Lannett announces 1-for-4 reverse stock split - Lannett announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m. Eastern Time on February 6. Beginning February 7, the company's common stock will trade on a split-adjusted basis. The common stock will continue to trade on the New York Stock Exchange under the symbol "LCI," but will trade under the new CUSIP number 516012 200. The reverse stock split was approved by Lannett Company's stockholders at the company's Annual Meeting of Stockholders held on January 25.

16:35 EST Magenta Therapeutics trading resumes

16:34 EST Energy Transfer LP raises quarterly dividend 15% to 30.5c per share - The dividend will be paid on February 21, 2023 to unitholders of record as of the close of business on February 7, 2023.

16:33 EST Arthur J. Gallagher raises quarterly dividend to 55c from 51c per share - The dividend will be payable on March 17 to Stockholders of Record as of March 3.

16:32 EST Lam Research announces restructuring, 7% workforce reduction - In a regulatory filing, the company said, "On January 23, 2023, the company commenced a workforce reduction that is intended to better align the company's cost structure with its outlook for the current economic environment and future business opportunities. The company expects the Restructuring Plan to entail a workforce reduction of approximately 1,300 employee positions, which is approximately 7% of the company's total number of employees. This Restructuring Plan is expected to be substantially completed by the end of the quarter ending June 25, 2023, but the timing of actions may vary by country based on local legal requirements. The Restructuring Plan is expected to result in total charges of approximately $80.0 million, to be incurred during the quarter ending March 26, 2023. These charges are expected to consist of cash charges related to one-time termination benefits associated with the workforce reduction. The company anticipates implementing further cost reduction activities over the next twelve months that are not part of the Restructuring Plan, some of which may result in additional expenditures and charges in future quarters."

16:30 EST Chevron raises quarterly dividend roughly 6% to $1.51 per share - The Board of Directors of Chevron Corporation declared a quarterly dividend of $1.51 per share, an increase of 9c per share or approximately 6 percent. The dividend is payable March 10, 2023, to all holders of common stock as shown on the transfer records of the Corporation at the close of business February 16, 2023. This increase puts Chevron on track to make 2023 the 36th consecutive year with an increase in annual dividend payout per share.

16:25 EST Magenta Therapeutics pauses MGTA-117 trial following Grade 5 SAE - Magenta Therapeutics announced that the latest participant dosed at the Cohort 3 level in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS experienced a Grade 5 Serious Adverse Event, or SAE, which is know as respiratory failure and cardiac arrest resulting in death, deemed to be possibly related to MGTA-117. The known information has been reported to the FDA as a Suspected Unexpected Serious Adverse Reaction, or SUSAR. After consultation with the trial's safety Cohort Review Committee and with the highest regard for patient safety, Magenta has voluntarily paused dosing in the clinical trial and is working to evaluate the totality of available data and determine next steps for the development of MGTA-117.

16:23 EST United Rentals resumes stock buybacks, to repurchase $1.0B in 2023 - The company states: "On October 24, 2022, the company's Board of Directors authorized a new $1.25 billion share repurchase program. The program was subsequently paused through the initial phase of the integration of the $2.0 billion Ahern Rentals acquisition, which closed in December 2022. The company plans to begin repurchases under the program in the first quarter of 2023, and intends to repurchase $1.0 billion of common stock during 2023."

16:17 EST FNCB Bancorp hikes dividend to 20% to 9c per share - On January 25, the Board of Directors of FNCB Bancorp declared a dividend of 9c per share for the first quarter of 2023, an increase of 1.5c per share, or 20 %, from 7.5 per share declared for the first quarter of 2022. The first quarter 2023 dividend is payable on March 15 to shareholders of record as of March 1, 2023.

16:16 EST Berkshire Hills Bancorp authorizes $50M share repurchase program - Berkshire Hills Bancorp has approved a share repurchase program pursuant to which the company is authorized to repurchase shares of company common stock at a total cost of up to $50M through December 31. This would result in the repurchase of approximately 4% of outstanding shares based on the current share price.

16:15 EST Calix says margins continued to move higher after bottoming in Q2 - The company said, "In the fourth quarter of 2022, our gross margin continued to move higher after bottoming in the second quarter of 2022 as our supply chain began to normalize and our platform solutions continued to grow. GAAP gross margin decreased 60 basis points year-over-year to 51.1% primarily as we received a U.S. tariff refund in the year ago period, while non-GAAP gross margin increased 30 basis points to 51.6% reflecting an improving supply chain and was slightly above our guidance range."

16:13 EST Full Truck Alliance responds to short-seller report - Full Truck Alliance issued a statement in response to a report issued by J Capital Research USA, a short seller, relating to the company on January 24. Statement highlights include: "The company firmly denies the allegations in the report that it has over-stated or falsified any operating or financial data. The company maintains the report contains numerous factual inaccuracies, false statements, unsupported speculations and flawed conclusions demonstrating a cursory and incomplete understanding of the company's industry and business operations...The company is considering the appropriate course of action to protect the interests of all of its shareholders. The company stands by the accuracy of its financial and operating data and other information published by the company and filed with the U.S. Securities and Exchange Commission. The company emphasizes its continued and unwavering commitment to maintaining high standards of corporate governance and internal control, as well as transparent and timely disclosure in compliance with applicable rules and regulations".

16:11 EST Tesla says Cybertruck on track to begin production later this year - Tesla said: "Cybertruck remains on track to begin production later this year at Gigafactory Texas. Our next generation vehicle platform is under development, with additional details to be shared at Investor Day [to be held on] March 1st, 2023."

16:10 EST LendingClub sees Q1 loan originations $1.9B-$2.2B - Sees Q1 pre-provision net revenue $55M-$70M.

16:09 EST IBM sees FY23 revenue growth consistent with MSD model - "Our solid fourth-quarter performance capped a year in which we grew revenue above our mid-single digit model. Clients in all geographies increasingly embraced our hybrid cloud and AI solutions as technology remains a differentiating force in today's business environment," said Arvind Krishna, IBM chairman and CEO. "Looking ahead to 2023, we expect full-year revenue growth consistent with our mid-single digit model."

16:01 EST Magenta Therapeutics trading halted, news pending

15:54 EST Microsoft says Xbox game 'Redfall' out May 2 - At its Developer Direct presentation, Microsoft's (MSFT) Xbox unit made a number of announcements related to upcoming first-party software. The company said that racing game "Forza Motorsport" will release in 2023, that Arkane-developed shooter "Redfall" will release May 2 for PC and Xbox Series X/S, and that Mojang's "Minecraft Legends" will release April 18 on PC, Xbox consoles, and PlayStation 4 and 5 (SONY). In addition, Microsoft's Tango, the studio known for "The Evil Within" and "Ghostwire Tokyo," announced a new game "Hi-Fi Rush," which released today for PC and Xbox Series X/S. Every single game discussed at the event will launch day one on Xbox Game Pass.

15:31 EST Robinhood responds to 'unauthorized' social media posts - Robinhood stated in a post to its corporate blog: "We're aware of the unauthorized posts from Robinhood Twitter, Instagram, and Facebook profiles, which were all removed within minutes. At this time, based on our ongoing investigation, we believe the source of the incident was via a third party vendor." Reference Link

15:00 EST CIBC raises prime lending rate to 6.7% from 6.45% - CIBC announced that it is raising its Canadian prime lending rate by 25 basis points from 6.45% to 6.7%, effective Thursday, January 26, 2023.

14:33 EST Mullen Automotive says 'no plans at current time to effect reverse split' - Mullen Automotive announces today after its reconvened special meeting of stockholders that all proxy proposals have been approved. "The company has no plans at the current time to effect a reverse split. The company has until March 6, 2023 to meet the Nasdaq minimum bid requirement of $1.00. If the share price of the company's stock falls short of the said requirement, the company intends to seek an extension from NASDAQ to meet the required threshold. If such extension is granted, compliance of the minimum $1.00 stock share threshold requirement may be extended for a further 180 days until approximately September 6, 2023. If the company still falls short of the minimum bid requirement, it will effect a reverse stock split at that time to maintain its Nasdaq listing compliance. Mullen is also a member of the Russell 2000 Index through June of 2023, which requires a minimum stock price of $1.00 for inclusion. The Russell Index will rebalance in June of 2023, at which time, if the share price of the company's stock falls short of the minimum $1.00 threshold required, Mullen will evaluate if it is in the best interest of shareholders to initiate a reverse stock split for continued inclusion in the Russell 2000 index," Mullen stated.

14:02 EST Jacobs approves $1B share buyback authorization, raises dividend by 13% - The Jacobs' board of directors has approved a new incremental share repurchase authorization program that authorizes the purchase of up to $1B of Jacobs' common stock. Under the 2023 share repurchase program, the company is authorized to repurchase shares through open market purchases, privately negotiated transactions or otherwise in accordance with applicable federal securities laws, and subject to other legal and business requirements and market conditions, at any time until January 25, 2026. The 2023 share repurchase program replaces the company's existing share repurchase program. The program may be suspended or discontinued at any time. Additionally, the board of directors has declared a quarterly cash dividend payable to shareholders in the amount of 26c per share of Jacobs common stock, an increase of 13% from its previous quarterly dividend of 23c. This dividend will be paid on March 24 to shareholders of record as of the close of business on Feb. 24. CFO Kevin Berryman said, "Jacobs is aligned to multiple secular growth trends that we believe offers the potential for compelling returns through a variety of economic scenarios. Our cash generative business model provides the ability to maintain an investment grade profile while accelerating long-term earnings power through share repurchases and consistently increasing our dividend to our shareholders."

13:59 EST Jacobs board approves $1B share repurchase authorization

13:35 EST Mount Rainier Acquisition Corp trading resumes

13:22 EST Integral Ad Science, Twitter launch Tweet-level brand safety insights - Integral Ad Science and Twitter announced the launch of third-party brand safety and suitability measurement on Twitter in the U.S. With Tweet-level analysis, advertisers can better understand the content that appears adjacent to their ads on Twitter's feed, the companies say. This advancement now provides Twitter advertisers with reporting that is aligned with Global Alliance for Responsible Media brand safety and suitability risk categories. For broader analytics, advertisers can access campaign-level reporting for overall metrics.

13:10 EST Mount Rainier Acquisition Corp trading halted, volatility trading pause

13:02 EST Aurinia says PTAB has terminated Inter Partes review - Aurinia Pharmaceuticals announced that the Patent Trial and Appeal Board of the United States' Patent and Trademark Office has terminated the Inter Partes Review it had instituted with respect to Aurinia's U.S. Patent No. 10,286,036.

12:31 EST NextEra believes FPL wouldn't be found liable for law violations - Commenting on the allegations of Florida state and federal campaign finance law violations on its Q4 earnings conference call, NextEra said that based on information in its possession, "We believe that FPL would not be found liable for any of the Florida campaign finance law violations as alleged in the media articles." The company said it plans to file a response seeking dismissal of the FEC complaint in the next few weeks, as it doesn't believe it is appropriate for the complaint to move forward.

12:15 EST Alvarium Tiedemann Holdings Inc trading resumes

12:03 EST Alvarium Tiedemann Holdings Inc trading halted, volatility trading pause

12:00 EST Li-Cycle falls -9.9% - Li-Cycle is down -9.9%, or -59c to $5.36.

12:00 EST RPC, Inc. rises 10.8% - RPC, Inc. is up 10.8%, or 93c to $9.52.

12:00 EST Stride rises 27.8% - Stride is up 27.8%, or $8.90 to $40.91.

11:18 EST Boeing plans to pause re-marketing of Max built for China

11:06 EST Boeing delaying 787 output increase to 5/month to late 2023, says CFO

10:55 EST Boeing sees 1Q23 EPS improved from 4Q22, but still in loss position

10:53 EST Boeing to maintain lower 787 production rate 'longer than expected'

10:41 EST Freeport-McMoRan sees Q1 copper sales 900M lbs - Sees Q2 copper sales 1.1B lbs, Q3 sales 1.07B lbs, Q4 sales 1.09B lbs. Sees Q1 gold sales 300,000 ozs, sees Q2 sales 460,000 ozs, sees Q3 sales 460,000 ozs, sees Q4 sales 480,000 oz. Sees Q1 molybdenum sales 20M lbs, sees Q2 sales 20M lbs, sees Q3 sales 20M lbs, sees Q4 sales 20M lbs. Comments taken from Q4 earnings presentation slides.

10:39 EST Boeing CEO: 'Realities are still the same,' including 'difficult supply chain - Comments taken from Q4 earnings conference call.

10:28 EST Freeport-McMoRan expects to complete feasibilty study for Bagdad this year - Says continues to plan next phase of growth. Says Americas Leach Initiative has compelling economics. Says identified new areas that were not pursued historically. Says continuing to target annual run rate of 200mm lbs by year-end. Says progressing feasibility study of Bagdad mine, expects to complete that this year. Says advancing plans to expand tailings infrastructure. Says in early stages of development of Lone Star. Says defined opportunity for major expansion at El Abra mine. Says planning to test new leaching technologies at El Abra. Says continuing development of Kucing Liar deposit. Says expects to have initial production from deposit toward the end of this decade.

10:15 EST Freeport-McMoRan says physical markets for copper have remained tight - Says generated 'strong margins' in Q4. Says proud of performance of team. Says team Indonesia has successfully grown production levels. Says made significant advances on new technologies to increase value. Says experienced significant volatility during 2022. Says prices continue to move higher in early 2023. Says copper's importance to the community has continued to grow.

10:00 EST Li-Cycle falls -9.6% - Li-Cycle is down -9.6%, or -57c to $5.38.

10:00 EST Freyr Battery falls -12.1% - Freyr Battery is down -12.1%, or -$1.20 to $8.70.

10:00 EST GasLog Partners rises 15.8% - GasLog Partners is up 15.8%, or $1.10 to $8.08.

09:48 EST Bit Brother signs LOI with Blockworx1 for $1.2M potential asset sale - Bit Brother signed an LOI with Blockworx1 or the potential sale of assets and services for total purchase price of $1,200,000. Blockworx1 is offering to sell 2-acre tract of land zoned for industrial use located at 5418 Lockheed Way, Abilene, TX 79603 that includes 5 MW of existing electrical load capacity with a potential to be scaled up to 10 MW of total electrical load capacity. Blockworx1 will also Development services to complete the build out of the aforementioned property for the purpose of cryptocurrency mining, including site design, selection and oversight of contractors, coordination in obtaining project approval and final inspection sign-off, negotiation and procurement of power purchase agreement(s) for 5 MW of electrical load, advisory and support for cryptocurrency mining hardware, and post-electrification site management to operationalize 5 MW of mining capacity.

09:47 EST Fisker falls -9.6% - Fisker is down -9.6%, or -70c to $6.60.

09:47 EST Web Street, Inc. rises 7.5% - Web Street, Inc. is up 7.5%, or $2.01 to $28.80.

09:47 EST Stride rises 30.4% - Stride is up 30.4%, or $9.72 to $41.72.

09:42 EST AT&T says outlook 'conservative' given economic uncertainty - Says economy currently stable, but not clear further out. Says swing factor could be a geopolitical event. Says Q3 should provide good view of Fed fiber funding.

09:35 EST Ucloudlink Group Inc trading halted, volatility trading pause

09:25 EST General Dynamics sees sequential increase in revenue throughout 2023

09:21 EST Atossa CEO says 'well positioned' to accelerate (Z)-endoxifen development - Atossa Therapeutics announces the issuance of a Letter to Shareholders from CEO Steven Quay, which read in part, "2022 was a year of significant progress for Atossa. We focused our development efforts on advancing our breast cancer program with our patented (Z)-endoxifen, the highest potency Selective Estrogen Receptor Modifier. We currently have Phase 2 studies ongoing in the prevention and treatment settings, both focused on areas of unmet medical need. Our goal is to both help reduce the incidence of breast cancer and change the treatment paradigm for patients who are not benefiting from currently approved drugs...As we look forward to 2023, we are well positioned to continue accelerating the development of (Z)-endoxifen. Both of our Phase 2 trials are ongoing, and we will provide enrollment and other updates as developments warrant throughout the year. We also have a strong balance sheet with no debt and cash, cash equivalents and restricted cash of approximately $117M as of September 30, 2022."

09:18 EST General Dynamics sees FY23 effective tax rate around 17%

09:16 EST General Dynamics expects CapEx to step back down below 2.5% of sales in FY23 - Comments taken from Q4 earnings conference call.

09:13 EST KAYAK and Affirm partner to help travelers book now and pay over time - Affirm (AFRM) announced a partnership with KAYAK (BKNG), the world's leading travel search engine, making Affirm the company's exclusive pay-over-time provider in the U.S. Now travelers have greater spending power and payment flexibility when booking trips on KAYAK...By selecting Affirm at checkout on KAYAK.com, approved KAYAK travelers can split the total cost of flights, accommodations, and rental and car sharing over $150 into monthly payments. From there, travelers will see the total cost of their purchase and will never pay more than they agree to upfront, as there are no late or hidden fees when paying over time with Affirm.

09:11 EST Modular Medical provides update on FDA submission strategy - Modular Medical provided an update on its insulin pump product. The company said, "In the process of assessing and optimizing materials and sterilization processes for its MODD-1 insulin pump, the Company has made sufficient progress on the full commercial version of the product that it now believes that the use of this commercial version for pre-submission validation testing constitutes its best and most cost-effective path forward. The full commercial version was designed in partnership with a tier-1, medical product manufacturer, and the Company believes that this new version will address all prior material compatibility issues, improve cost of goods and usability, and reduce redundant testing of different versions of the MODD-1. Given the expected arrival time of key production equipment and the resulting timing of tests of both the equipment and the product itself, the Company now expects to make its submission to the U.S. Food and Drug Administration during the quarter ended December 31, 2023."

09:10 EST Acasti receives extension to regain compliance with minimum bid requirement - Acasti Pharma announces that it has received notification from the NASDAQ Listing Qualifications Department that it is eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the minimum $1.00 per share requirement for continued listing. On July 27, 2022, Acasti received notification from NASDAQ for not maintaining a minimum bid price of US$1.00 per share for 30 consecutive business days. The Company was given 180 calendar days, or until January 23, 2023, to regain compliance.

09:10 EST Daktronics reaches agreement to extend near-term credit facility maturity - Daktronics entered into an amendment to its credit agreement with its current lender, U. S. Bank National Association, to extend the maturity of $10 million of its $45 million credit facility to May 1, 2023. The remaining $35 million of the credit facility matures on April 29, 2025. The extension of liquidity is the result of the efforts of an independent Strategy and Financing Review Committee of the Daktronics Board of Directors, which was formed in December 2022, to address the Company's near-term credit needs and to examine alternatives for strengthening the Company's longer-term financial structure and liquidity profile.

09:07 EST Volkswagen and onsemi in strategic collaboration on silicon carbide for EVs - onsemi announced that it signed a strategic agreement with German Volkswagen AG (VWAGY) to provide modules and semiconductors that enable a complete electric vehicle traction inverter solution for VW's next-generation platform family. The semiconductors are part of an overall system optimization and provide a solution that will support the front and rear traction inverters in the VW models. As part of the agreement, onsemi will deliver in a first step its EliteSiC 1200 V traction inverter power modules. The EliteSiC power modules are pin to pin compatible to easily scale the solution to different power levels and types of motors. "The superior performance and quality of onsemi's traction inverter modules together with our joint efforts to create the best system solution enable us to deliver the outstanding driving experience and quality customers expect from a VW group vehicle," said Karsten Schnake, head of the operative and strategic semiconductor taskforce COMPASS at Volkswagen AG. "

09:06 EST RealReal appoints Koryl as CEO, board member - The RealReal (REAL) announced that John Koryl will join the company as its Chief Executive Officer and as a member of its Board of Directors, effective February 6, 2023. The company's Co-Interim Chief Executive Officers, Rati Sahi Levesque and Robert Julian, will remain with the company as President and Chief Operating Officer, and Chief Financial Officer, respectively. Koryl most recently served as President, CTC Digital, at Canadian Tire Corporation (CDNAF).

09:04 EST Branch selects Verisk's LightSpeed for Personal Lines platform - Branch is delivering fast, simple transactions for consumers that improve the customer experience and lift conversion rates by integrating granular reliable data on household risk from Verisk. With Verisk's LightSpeed for Personal Lines platform as part of its tech-stack, Branch delivers reliable, bundled auto and homeowners quotes in seconds, requiring only a name and address. Branch's strategy embraces a new economic model, supporting profitable growth and optimized workflows.

09:03 EST Matterport releases inaugural ESG report - Matterport released the company's first Environmental, Social, and Governance report that assesses the impact of Matterport's products and programs toward driving sustainable and equitable outcomes. The report, based on 2021 data, provides a benchmark to establish company-wide ESG goals and commitments. The topline environmental findings confirm Matterport's digital twins are highly effective at helping customers achieve sustainability goals. Matterport's revolutionary technology allows for the creation of high-precision, immersive 3D digital twins of millions of buildings and other real-world locations, enabling people globally to work smarter and more sustainably by reducing the need for business travel and easing the strain on the environment. The company commissioned independent carbon accounting experts, Minimum, to calculate the emissions reduction potential of using Matterport's digital twin platform. The findings were compelling, revealing a significant reduction in emissions through the use of Matterport's digital twin technology: In 2021, Matterport's solution helped customers prevent an estimated 374,312 tonnes of CO2e from being released into the atmosphere globally through reduced business travel - equivalent to the emissions of over 80,000 passenger cars driven for one year. A Matterport digital twin can reduce emissions by an average of 0.15 tCO2e over its lifetime - equivalent to not driving a car for 444 miles. Utilizing digital twins for remote facilities management results in greater emissions prevention than in most other applications.

09:01 EST Millicom up 16% after FT report on takeover interest

08:50 EST AT&T expects 'challenging' macroeconomic environment near term - Expects wireless industry to return to "normalized levels."

08:44 EST Vornado, Rudin complete 350 Park Avenue, 40 East 52nd Street transactions - Vornado Realty Trust and Rudin announced that they have completed the previously announced transactions with Citadel Enterprise Americas and with an affiliate of Kenneth Griffin, Citadel's Founder and CEO, relating to 350 Park Avenue and 40 East 52nd Street. All third-party approvals have been obtained and the master lease and other agreements are effective.

08:43 EST Enlivex announces recommendation, IMOH clearance for Phase I/II trial - Enlivex Therapeutics announced that an independent Data and Safety Monitoring Board, DSMB, has completed its prespecified data review for the first cohort of patients in the Company's ongoing Phase I/II cell therapy clinical trial of Allocetra in patients with advanced-stage solid tumors. The Israeli Ministry of Health, IMOH, also reviewed the data and provided regulatory clearance to continue the study and open the study's additional cohorts. The DSMB based its review on available safety data for the three enrolled patients in the first cohort in which three, once-weekly, low starting doses of AllocetraTM were administered as monotherapy. The dose-limiting toxicity period extended for one week following the last administration with an overall follow-up of 21 days. There were no mortalities nor DSMB-identified safety signals in the first cohort, and the DSMB recommended that the study continue as designed. Following the DSMB recommendation, the IMOH reviewed the safety data for the first cohort and provided a regulatory clearance to initiate the recruitment of patients into the two following cohorts in the study, both of which will be administered higher AllocetraTM doses - one as monotherapy and the other in combination with anti-PD1 therapy. Oren Hershkovitz, Ph.D., CEO of Enlivex, commented, "We are pleased with the safety profile of AllocetraTM as demonstrated in the first three patients in this trial. We look forward to initiating the next two cohorts in which higher doses of AllocetraTM will be administered in patients, allowing Enlivex to obtain additional safety data as well as a potential indication of effect."

08:42 EST Jaguar Health announces milestone in process of establishing Indena - Jaguar Health announced that the required procedure of registering the source of the active pharmaceutical ingredient of crofelemer with the Agenzia Italiana Del Farmaco, the Italian Medicines Agency, has been completed. Resultingly, batches of crofelemer API manufactured by Milan, Italy-based Indena S.P.A. can now be used by Jaguar for further development work.

08:41 EST RDE's Restaurant.com, Entelliment celebrate ten years of collaboration - RDE and Entelliment are pleased to celebrate their 10 years of working together and the 10th year of Restaurant.com's Night Out. Together, Restaurant.com and Entelliment, are seeing positive trends in growth and consumer experience for their entertainment packages in regards to both savings and day of live entertainment and dining. In 2022, Restaurant.com saw a 66.5% increase in sales for live show offers compared to the prior year. More live shows are available, and consumers are excited to go out to dine at restaurants in combination with going to a show, concert or sporting event. Consumers are turning to experiences more than material items to be more present and personal in their everyday life.

08:40 EST ToughBuilt expands distribution agreement with Sodimac - ToughBuilt Industries is pleased to announce that the Company is expanding its distribution agreement with Sodimac, the largest home improvement and construction supplier in South America; In this extended agreement, stores in Chile, Peru, Argentina, Colombia, Brazil, and Uruguay will initially begin with 15 SKUs in-store and brings 23 SKUs to Sodimac's online marketplace.

08:39 EST Clearmind announces presentation of psychedelic-derived obesity treatment - Clearmind Medicine announced that Professor Joseph Tam, D.M.D., Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating obesity, presented the latest results at Isranalytica 2023. The presentation, titled "The Psychoactive Drug 5-Methoxy-2-aminoindane Ameliorates Obesity and its Metabolic Complications," included data from recently announced pre-clinical results demonstrating efficacy of Clearmind's drug candidate MEAI for treating obesity and metabolic syndrome. Isranalytica 2023, the Annual Meeting of the Israel Analytical Chemical Society, ranks as one of the world's largest annual analytical chemistry conferences. Professor Joseph Tam, D.M.D., Ph.D., heads the Obesity and Metabolism Laboratory, and he is an Associate Professor of Pharmacology at the Hebrew University's Institute for Drug Research. Along with Dr. Saja Baraghithy, Ph.D., he led the pre-clinical trial as part of Clearmind's robust collaboration with the Hebrew University and its technology transfer company Yissum.

08:37 EST Allogene announces publication of preclinical study on DLL3, AlloCAR T - Allogene Therapeutics announced the publication of a preclinical study demonstrating delta-like ligand 3, DLL3, is a promising tumor target for AlloCAR T in small cell lung cancer, SCLC. The findings were published in Clinical Cancer Research, a journal of the American Association for Cancer Research, AACR. This study describes the selection of ALLO-213 as an allogeneic CAR T development candidate targeting DLL3 from a large number of single chain variable fragment (scFv)-based anti-DLL3 CAR candidates. The selection of ALLO-213 was based on potency and specificity against SCLC cell lines in vitro and in vivo, including cell lines with very low antigen density to establish sensitivity. The results from the pre-clinical study showed: No DLL3 on target toxicity was observed in preclinical models supporting a potentially attractive safety profile; Clinical DLL3 CAR candidates controlled DLL3+ tumor growth in mice without normal tissue toxicity

08:35 EST Phio Pharmaceuticals approves 1-for-12 reverse stock split - Phio Pharmaceuticals announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-12. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 26, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 26, under the Company's existing trading symbol, "PHIO." At such time, the Company's common stock will also commence trading with a new CUSIP number, 71880W402. The reverse stock split is being implemented to increase the per share trading price of the Company's common stock, for the purpose of ensuring a share price high enough to comply with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. The Company has retained its transfer agent, Computershare Trust Company, act as its exchange agent for the reverse split.

08:34 EST SciSparc to restructure, transfer pharmaceutical activities to new subsidiary - SciSparc announced that its board of directors has resolved on pursuing a restructuring plan which involves transferring its pharmaceutical activities to a new wholly owned subsidiary. As part of the plan, SciSparc will examine the possibility of listing this new subsidiary on a leading stock exchange, while maintaining its control interest. The reorganized structure will allow the Company to continue to control its current activities. In addition, the Company will explore other potential new opportunities, activities and investments in a variety of sectors.

08:33 EST Hertz and AAA sign new agreement - Hertz and AAA, one of North America's largest membership organizations, have extended their exclusive, 45-year relationship with the signing of a new five-year agreement. The relationship, which commenced in 1978 and is one of Hertz and AAA's most longstanding, provides AAA members with a comprehensive suite of car rental benefits, discounted rates, and other exclusive perks which include: Everyday savings off the base rate rental; No charge for additional drivers who are also AAA members; Free use of one child, infant or booster seat; Young renter fee waived for members ages 20-24; Access to Hertz Gold Plus Rewards loyalty program, which offers additional and exclusive benefits.

08:27 EST Duos Technologies reports100% renewal rate of recurring revenue contracts - Duos Technologies Group announced that it has achieved a 100% renewal rate of its recurring revenue contracts throughout the full year 2022 with $2 million cash inflow from those contracts expected to be received during the first quarter of 2023.

08:25 EST Holiferm and Sasol Chemicals team to produce MELs, no terms - Holiferm Limited and Sasol Chemicals, a business unit of Sasol, announced a collaboration to produce and market rhamnolipids and mannosylerythritol lipids MELs. This collaboration expands the partnership announced in March between the two companies to develop and commercialise another biosurfactant product, sophorolipids. The partnership will use Holiferm's proprietary technology to develop the fermentation-derived biosurfactants. Sasol and Holiferm will develop and commercialise formulations and applications for the new molecules. "The imminent commercial launch of our second and third products validates Holiferm's process to develop process technologies to produce chemicals from natural raw materials and enable their broad commercialisation," said Vicky De Groof, Chief Technical Officer of Holiferm. "It is also a testament to the exceptional work of the laboratory team."

08:22 EST Aytu BioPharma regains Nasdaq minimum bid price compliance - Aytu BioPharma announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement. On January 23, 2023, Nasdaq confirmed in that for the ten consecutive business days, from January 6, 2023 to January 20, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and the matter is closed.

08:21 EST Ensysce Biosciences initiates final stage of Phase 1 study of PF614-MPAR - Ensysce Biosciences announced the initiation of the final stage of the Phase 1 study of PF614-MPAR. PF614-MPAR is the overdose protection version of its lead product, PF614, and this key study is being conducted in healthy subjects by Dr. Maria Bermudez MD, at Quotient Sciences, Miami, Florida. PF614, a TAAP prodrug of oxycodone, has a number of safety features designed to reduce abuse, including its extended-release profile that has been shown to reduce 'drug liking' in recreational drug users. Additionally, its requirement for exposure to the enzyme trypsin to release oxycodone reduces the ability of recreational users to chew, crush and snort, or manipulate and inject to change the opioid release profile. The combination product PF614-MPAR has another layer of safety, with an added trypsin inhibitor to prevent overdose. PF614-MPAR is designed to provide optimal pain relief at prescribed doses. Accidental or intentional overdose is designed to be limited by the overdose protection built into each capsule with the addition of Ensysce's formulated trypsin inhibitor, nafamostat. With MPAR technology, the target dose of one or two prescribed PF614-MPAR capsules will release the expected concentration of oxycodone required to provide pain relief as intended. However, when three or more capsules are taken, exceeding the target dose, the increased exposure to nafamostat progressively inhibits the release of oxycodone from the excess PF614 ingested. This allows the inactive drug to pass through the body, thus averting an overdose. The recently completed initial stage of the trial sought to optimize PF614-MPAR for both release rate and ratio of the combination. Data from the trialdemonstrated that PF614-MPAR could deliver oxycodone similarly toPF614, which was the goal of the study. In line with expectations, the results of the study demonstrated that an overdose of PF614-MPAR would result in diminished oxycodone release and uptake as compared to an equivalent amount of PF614. In the final stage of the study, the selected PF614-MPAR formulation will be evaluated by measuring oxycodone release from increasing dose units delivered to a group of healthy subjects.

08:19 EST Amdocs, Ateliere collaborate to help media companies with content demand - Ateliere Creative Technologies and Amdocs announced a collaboration that allows media companies to better meet growing content demands. As part of the deal, Ateliere has selected Amdocs' Vubiquity as their preferred managed services partner. Customers with media supply chains fully managed by Ateliere Media Services, also running on Ateliere Connect, will now be aided by Vubiquity's media services and global support operation. Additionally, Vubiquity will expand its existing video processing technology to run the cloud-native Ateliere Connect media supply chain platform. This will allow Vubiquity to reach additional platforms above and beyond the 2800+ destinations it delivers to today and offer further scalability and flexibility for existing and future clients on how it can continue to package and distribute content faster and cost-effectively.

08:14 EST Nikola: Biagi Bros. to take delivery of 15 Nikola Tre FCEVs in Q4 - Nikola announced that Biagi Bros. Inc. plans to take delivery in the fourth quarter of 2023 of 15 Nikola Tre hydrogen fuel-cell electric vehicles in Ontario, Calif. The FCEV trucks are expected to put in over 100,000 miles per year, to support the round-the-clock operations.

08:14 EST Telus invests $5M in UWindsor as part of multiyear agreement - The University of Windsor and TELUS announced the launch of a 5G connected campus and commercial lab to support advanced research with 5G technology and establish the university as a go-to centre for innovation. TELUS is investing $5 million as part of a multi-year agreement that began in 2020 to fuel the development of new applications for 5G technology. The collaboration will not only support multidisciplinary research in the agriculture, advanced manufacturing, and connected and autonomous vehicles ectors, but will transform UWindsor campuses to enhance teaching, innovation and collaboration. Beyond the development of the 5G commercial lab, the central space in the Ed Lumley Centre for Engineering and Innovation will be named the TELUS Atrium. The area is fostering collaborative concept discovery, ideation and creativity as students and researchers build solutions that meet today's global challenges

08:13 EST Fujifilm completes asset purchase of Inspiratas digital pathology business - Fujifilm has completed its asset purchase of Inspirata, Inc.'s digital pathology business effective January 23, 2022. The Dynamyx digital pathology technology and U.S. employees who supported that business, including all Dynamyx product development, are now part of FUJIFILM Healthcare Americas Corporation. To deliver on the significant demand and market growth potential of the digital pathology market, Fujifilm has also established a pathology division of its Medical Informatics business. This new pathology division is led by Dr. Mark Lloyd, business leader and head scientist of the Dynamyx product. Mark brings more than 20 years of pathology experience to the organization.

08:11 EST EU commercial vehicle registrations down 5.1% in December - In December, new commercial vehicle registrations in the EU retreated by 5.1%, as component shortages continued to weigh on vehicle availability, reported the European Automobile Manufacturers Association. "All vehicle segments performed worse than in December 2021, contributing to the overall negative result. During the month, the performance of the four major markets was mixed," the group said. Publicly traded truck makers and suppliers include Daimler AG (DDAIF), Paccar (PCAR), CNH Industrial (CNHI), Navistar (NAV), Cummins (CMI) and Allison Transmission (ALSN).

08:09 EST Vera Therapeutics to host KOL webinar on atacicept - Vera Therapeutics announced that it will host a virtual key opinion leader event featuring Jonathan Barratt, PhD, FRCP, from the University of Leicester, who, together with Vera Therapeutics management, will provide an update on atacicept's ORIGIN Phase 2b data in IgA nephropathy. Atacicept is the Company's potential best-in-class, disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator and a proliferation-inducing ligand. ORIGIN is a multinational, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of atacicept in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression despite available ACE or ARB therapy.

08:09 EST Axcelis announces follow-on shipments of the Purion H current implanter - Axcelis Technologies announced follow-on shipments of the Purion H high current implanter to multiple fabs in support of the customer's most advanced logic device technology manufacturing ramp. The systems shipped in the Q4. Purion H ion implanters bring the industry-leading process control of our medium current platforms to the full range of demanding, high-current applications. The flexibility of the platform enables us to tailor Purion H to the specific energy or dosing requirements of your application.

08:08 EST RYVYL Inc. provides corporate update on restatement of financial statements - RYVYL provided a corporate update following the Company's January 20th Current Report on Form 8-K filing with the SEC regarding non-reliance on previously issued financial statements. The impact of the restatement of the financial statements for the annual and interim periods for the year ended December 31, 2021 and the interim periods for the first three calendar quarters of the year ended December 31, 2022 is expected to be limited to decreases to total revenue, increased net losses, decreases to total assets, and decreased total stockholders' equity, as noted in the 8-K. The Company expects that cash, operating margins, and processing volumes as reported in our previously issued financial statements will not be materially impacted by the restatements. The Company anticipates filing the restatements of the previously issued financial statements as soon as practicable. The Company plans on filing the restated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2022 and in any other filings that may be necessary or appropriate.

08:07 EST Comerica announces promotion of three executive leaders - Comerica announced that, effective January 27 it is promoting three executive leaders to newly established positions: Peter Sefzik, Executive Vice President, Executive Director, Commercial Bank, will assume the role of Senior EVP, Chief Banking Officer; Megan Crespi, EVP, Chief Enterprise Technology and Operations Services Officer, will assume the role of Senior EVP, COO; and Megan Burkhart, EVP, Chief Human Resources Officer, will assume the role of Senior EVP, Chief Administrative Officer. Sefzik, Crespi and Burkhart will continue to report to Comerica Chairman and CEO Curt Farmer. Sefzik will oversee the revenue teams, including Commercial Bank, Retail Bank, and Wealth Management, as well as Marketing and Customer Experience. In his new role, he will expand his focus on customer relationships and growth across all three major business segments and through our marketing investment. Sefzik assumed the role of EVP, Executive Director of the Commercial Bank in 2018, where he is responsible for all lines of business in the Commercial Bank segment of Comerica, which includes General Middle Market, Business Banking, 14 Specialty Lines of Business, Treasury Management & Capital Markets. Crespi will oversee Technology, Enterprise Security, Lending and Trade Services, Corporate Real Estate, Customer Contact Center, and two additional areas, Data and Analytics and a new Digital function, which will focus on Comerica's digital transformation. She joined Comerica in March 2020 to oversee the bank's enterprise payments, lending & trade services, real estate & security, technology and cybersecurity units. Burkhart will oversee Human Resources, the Business Program Management Office and Corporate Responsibility. Burkhart was named the Chief Human Resources Officer in 2010, leading Diversity & Inclusion, HR Operations & Risk, HR Consulting, Talent Management & Learning, Organizational Change Management, Talent Acquisition and Total Rewards. She joined Comerica in 1997 and served in a variety of HR-related positions, including Senior Vice President and Director of Compensation.

08:07 EST Jasper Therapeutics announces pricing of $90M public offering - Jasper Therapeutics announced the pricing of its underwritten public offering of 60,000,000 shares of its common stock. Each share of common stock will be sold at a public offering price of $1.50 per share, for gross proceeds of approximately $90 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses. In addition, Jasper has granted the underwriters a 30-day option to purchase up to 9,000,000 additional shares of its common stock, at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Jasper. The offering is expected to close on or about January 27, 2023, subject to the satisfaction of customary closing conditions. Credit Suisse Securities and William Blair & Company, L.L.C. are acting as the active book-running managers for the proposed offering. Oppenheimer & Co. Inc. is acting as a passive book-running manager for the proposed offering.

08:06 EST Capricor announces 18-month results from ongoing HOPE-2 OLE study of CAP-1002 - Capricor Therapeutics announced positive 18-month results from its ongoing HOPE-2 open label extension, OLE, study in patients with later-stage Duchenne muscular dystrophy, DMD. Data from the OLE study continues to show evidence for disease modification with statistically significant differences in the Performance of the Upper Limb scale in the CAP-1002 original treatment group when compared to the original placebo group from HOPE-2. In addition, disease progression is attenuated equally in both groups once patients begin treatment in the OLE. The study met its primary endpoint at the one-year timepoint and continues to show statistically significant improvements on the Performance of the Upper Limb scale for patients treated with CAP-1002 at 18-months. In the study, CAP-1002 was made available to the original 20 patients enrolled in the HOPE-2 study. Of those, 13 entered and 12 completed 18-months of study follow-up. The breakdown of patients included seven from the original placebo group and six from the original CAP-1002 treatment group. All patients were off CAP-1002 or placebo for a mean of approximately one-year before resumption or initiation of therapy under the HOPE-2 OLE program. As in HOPE-2, CAP-1002 was administered quarterly and current results are from the 18-month analysis. Linda Marban, Ph.D., CEO of Capricor, commented, "In the OLE phase of the HOPE-2 study, we observed statistically significant slowing of the progression of disease across patients treated with CAP-1002. We are extremely pleased by the robust and consistent results observed to date, which, together with the favorable safety/tolerability profile, suggest that CAP-1002 holds promise as a potential anchor therapy for DMD patients. Further, the long-term efficacy and potential disease modification effect will augment our clinical package as we continue on our regulatory pathway towards potential approval of CAP-1002 for treatment of patients with DMD. We thank the patients, their families, caregivers, and the broader Duchenne community for working with us on this promising therapy."

08:05 EST Univar Solutions Brazil expands relationship with Dow - Univar Solutions Brasil, a subsidiary of Univar Solutions, announced an expanded distribution relationship in Brazil with Dow. The new agreement will strengthen Univar Solutions' homecare & industrial cleaning portfolio in Brazil with the addition of cleaning brands ACUSOL, SupraCare, and others. Univar Solutions and Dow Expand Relationship in Brazil to Include the Homecare and Industrial Cleaning Market"Our enhanced partnership with Dow represents a major step for our homecare and industrial cleaning business in Brazil. Building on our close collaboration with Dow in North America and Europe, the new agreement will increase the depth and breadth of our portfolio and customer reach in this region, and demonstrates the importance of strong global supplier relationships," said Jorge Buckup, president, Latin America for Univar Solutions. Univar Solutions' customers in Brazil will have access to Dow brands that are used in home and industrial cleaning applications and products such as dish, laundry, and surface cleaners.

08:04 EST Triumph Group awarded contract from Airbus - Triumph Group (TGI) announced that its Actuation Products and Services business has been awarded a contract from Airbus (EADSY) to provide A220 On Wing Emergency Exit Door control cables. The multi-year contract will be performed in Shelbyville, Indiana.

08:03 EST Clear Secure launches at Raleigh-Durham International Airport - Clear Secure announced launching its identity verification technology at Raleigh-Durham International Airport, bringing frictionless and predictable travel experiences to its 50th airport.

07:55 EST Iris Energy president Lindsay Ward to retire - Iris Energy announced the retirement of its President, Lindsay Ward. Having supported Iris Energy's first phase of growth post listing, Lindsay is retiring as part of his transition away from a full-time executive career to pursue additional Non-Executive Director opportunities. Lindsay will remain with the Company until June 30, 2023 to assist with energization of the Company's 600MW site at Childress, Texas and to provide general support to the business. Following this date, Lindsay and the Company may explore ways in which Lindsay can continue to work with the business in a non-executive capacity.

07:45 EST Shopify announces changes to 2023 plan pricing - In a blog post yesterday, Shopify's Kaz Nejatian stated in part: "When Shopify was started in 2006, it was a novel product with a novel idea: to provide the best commerce tools in the world to all merchants of all sizes, to make commerce better for everyone. A lot has changed since then, but a few things haven't: why we do it and who we do it for. The price we charge for access to the best tools in commerce has remained largely unchanged for the last 12 years. Today, after much deliberation, we're announcing a change in favor of better serving our mission and our merchants: We are updating our pricing for Basic, Shopify, and Advanced plans: Our pricing page outlines the new prices. Existing merchants won't see a price change for three months. The updated pricing is now in effect for new merchants, and they can explore Shopify and build their businesses for as little as $1 per month during their paid trial. Shopify is still the best value in commerce." Reference Link

07:43 EST Avant Brands announces strategic objectives for 2023 - Avant Brands is pleased to provide a corporate update. The Company executed two key transactions recently that are expected to contribute to the ongoing growth of Avant. On December 8, 2022, the Company announced that Avant Brands K1, an entity of which Avant owns 50% of the issued and outstanding shares, was the successful bidder to purchase The Flowr Group, including its 185,000 square-foot production facility in Kelowna, BC. On December 19, 2022, the Company announced it has entered into a binding share purchase agreement to acquire the remaining 50% equity stake of 3PL Ventures for its flagship production facility in Vernon, BC. The Flowr Facility remains fully operational and is expected to increase Avant's production capabilities by approximately 60%, which has the potential to make Avant one of the largest indoor producers of high-quality cannabis in Canada. The Company expects to make certain modifications to production processes at the Flowr Facility throughout the 2023 fiscal year to align with Avant's cultivation methodologies in order to continue striving to produce the premium quality products that its customers demand. The acquisition of the remaining 50% of 3PL will provide Avant's wholly owned subsidiary, GreenTec Holdings Ltd., with full ownership of the 3PL Facility, which is expected to generate meaningful cash flows over the course of the 2023 fiscal year. With the buyout of the non-controlling interest in 3PL, the Company will eliminate the shareholder loan of approximately $12.0 million owing to the non-controlling shareholder, F-20 Developments, which, in accordance with the terms of the shareholders agreement for 3PL, had first priority to receive the majority of 3PL's operating free cash flow in order to repay this shareholder loan. Fiscal 2023 Strategic Objectives and Outlook: Upon closing of the acquisitions of Flowr Okanagan and 3PL, Avant's strategic objectives and outlook for the 2023 year include: Increasing production through the Flowr Facility and the 3PL Facility; Implementing modifications to the Flowr Facility to facilitate production of Avant premium cannabis flower; Fulfilling all Provincial government purchase orders and export demand; Exploring new global markets for exporting product, leveraging the Company's reputation in existing markets, such as Israel and Australia; Launching new cultivars from Avant's extensive library of genetics; Continuing to operate in a fiscally responsible manner, while seeking opportunities to reduce the Company's overall cost of production; and Continuing to explore contract growing or acquisition opportunities to the extent that the acquisition of Flowr Okanagan does not completely fulfill unmet customer demand. As of November 30, 2022, the Company had approximately $7 million in cash and no interest-bearing debt on the balance sheet. As of the date of this news release, the Company has approximately $6.9 million in cash to continue to fund this expected growth.

07:40 EST Sonoma, EMC announces DOD DAPA registration for Microcyn products - Sonoma Pharmaceuticals announced that Microcyn Rx products have received a Distribution and Pricing Agreement for distribution by the Defense Logistics Agency. The DAPA enables our partner, EMC Pharma, to enter into distribution agreements for Microcyn Rx products with federal customers. The U.S. government is the world's largest purchaser of good and services. Approximately half of EMC Pharma's customers are U.S. government entities, including VA hospitals, the Department of Defense, the Federal Bureau of Prisons, as well as state and local prison systems. EMC Pharma is a 100% minority-owned and a certified Minority Business Enterprise. The DAPA approval process was a coordinated effort by Sonoma and EMC Pharma and resulted in obtaining DAPA # SP0200-22-H-0034 for Sonoma's Microcyn Rx products including wound care, prescription dermatology products, Celacyn and Levicyn, and prescription eye care Acuicyn.

07:39 EST Monro reports preliminary January comp store sales up 8%

07:38 EST ARway launches Image Access Point technology - The company said, "ARway is pushing the envelope of what's possible by launching the Company's new Image Access Point technology. Image recognition and tracking for localization and wayfinding is newly developed technology that uses computer vision to trigger from a brand image or logo. Developers can now pre-select which images will serve as AR triggers, also known as Image Access Points. The Company plans to file an application to have this technology patented in Q1, 2023."

07:37 EST Marathon Gold exercises buy back option on Valentine royalty - Marathon Gold Corporation (MGDPF) reports that it has provided notice to Franco-Nevada Corporation (FNV) of its intention to exercise its option to acquire 0.5% of the 2.0% net smelter returns royalty on the Valentine Gold Project held by FNV. The closing of the exercise of the Buy Back Option is scheduled for February 22, 2023 at which time the Company shall pay to FNV consideration of $7M, thereby reducing the NSR on the Project from 2.0% to 1.5%.

07:33 EST Boeing: Certification efforts continuing on 737-7, 737-10

07:33 EST Abbott CEO says 'R&D pipeline continues to be highly productive' - "We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions," said Robert B. Ford, chairman and CEO, Abbott. "Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."

07:32 EST Boeing reaffirms guidance for $4.5B-$6.5B operating cash flow in FY23 - Reaffirms guidance for $3B-$5B of free cash flow.

07:27 EST Alterity Therapeutics launches ATH434 Phase 2 trial in Italy - Alterity Therapeutics announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy is now open for enrollment in Italy. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA. The study will evaluate the effect of ATH434 treatment on neuroimaging and protein biomarkers to demonstrate target engagement and clinical endpoints to demonstrate efficacy, in addition to assessments of safety and pharmacokinetics. The selected biomarkers, including brain iron and aggregating alpha-synuclein, are important contributors to MSA pathology and are therefore appropriate targets to demonstrate drug activity. Wearable sensors will also be employed to evaluate motor activities that are important to patients with MSA. The study is expected to enroll approximately 60 adults to receive one of two dose levels of ATH434 or placebo. Participants will receive treatment for 12 months which will provide an opportunity to detect changes in efficacy endpoints to optimize design of a definitive Phase 3 study.

07:20 EST Fennec says updated NCCN guidelines recommend PEDMARK - Fennec Pharmaceuticals announced that the National Comprehensive Cancer Network has updated its clinical practice guidelines for Adolescent and Young Adult Oncology to include PEDMARK to help reduce the risk of ototoxicity associated with cisplatin use in pediatric patients with localized, non-metastatic solid tumors.

07:17 EST Akoustis announces closing of public offering of common stock - Akoustis announced the closing of its previously announced underwritten public offering of 12,545,454 shares of its common stock at a price to the public of $2.75 per share, which included the exercise in full by the underwriters of their option to purchase 1,636,363 additional shares of Akoustis' common stock. Net proceeds to Akoustis, after deducting the underwriting discount and estimated offering expenses payable by Akoustis, were approximately $32.0 million. Akoustis intends to use the net proceeds from the offering to fund operations and the growth of its business, including capital expenditures, working capital, research and development, the commercialization of its technology, servicing its outstanding debt, potential strategic transactions, and other general corporate purposes. Akoustis management participated in the offering with over $1 million in aggregate investments, including an investment of $900K by Akoustis Founder & CEO, Jeff Shealy. B. Riley Securities acted as the sole book-running manager for the offering, and Craig-Hallum Capital Group and Roth Capital Partners acted as co-managers for the offering.

07:15 EST Extreme Networks CFO Remi Thomas to resign and Cristina Tate named interim CFO - Extreme Networks announced that its CFO, , Remi Thomas, will resign from his position at Extreme. Thomas will remain with Extreme until February 16. Extreme has initiated a search for a CFO with the assistance of a leading executive search firm. Senior Vice President and head of Financial Planning & Analysis, Cristina Tate, will take over as interim CFO. She is responsible for long-term planning, budgeting, forecasting, and management reporting and oversees all finance business partnerships across the various corporate functions at Extreme. She is also the Chair of Extreme's Women in Networking (WIN) alliance. Prior to Extreme, Tate was at Micro Focus and Hewlett-Packard's Software business unit. She holds a Bachelor of Arts in economics and mathematics from the University of California, Santa Barbara.

07:14 EST Nokia appoints Esa Niinimaki as CLO - Nokia announced the appointment of Esa Niinimaki as Chief Legal Officer and member of the Group Leadership Team, effective January 25, 2023. Esa has worked at Nokia for more than 15 years where he has held multiple positions, most recently Interim CLO. Esa continues to be based in Finland and report to Nokia's President and CEO, Pekka Lundmark.

07:12 EST SpringBig announces integration with KORONA POS - springbig introduced a new integration with KORONA POS from software vendor COMBASE. KORONA POS and springbig's bidirectional integration will allow merchants to apply and award loyalty offerings directly from KORONA POS at checkout. Merchants will also be able to enroll new members into the loyalty program from either the POS or one of Springbig's many enrollment tools. The Company's marketing platform seamlessly integrates with KORONA POS to provide marketing segmentation based on sales data. This allows highly targeted and strategic campaigns to drive business and reach consumers in a highly personalized way.

07:11 EST Tango Therapeutics provides upcoming milestones - Upcoming Milestones: A dose escalation update is expected from the Phase 1/2 clinical trial of TNG908 in patients with MTAP-deleted solid tumors during the first half of 2023. The initiation of the Phase 1/2 clinical trial for TNG462, a next-generation MTA-cooperative PRMT5 inhibitor, is expected in mid-2023. The IND filing for TNG260, a first-in-class CoREST inhibitor, is on track for the first half of 2023. The IND filing for TNG348, a novel USP1 inhibitor that is being developed for treatment of BRCA1 and BRCA2-mutant cancers, is on track for mid-2023.

07:10 EST Tango Therapeutics announces FDA clearance of IND application for TNG462 - Tango Therapeutics announced that the U.S. Food and Drug Administration, FDA, has cleared an Investigational New Drug, IND, application for TNG462, a next-generation MTA-cooperative PRMT5 inhibitor for the treatment of patients with MTAP-deleted cancers. The Company also announced that TNG908 was granted Orphan Drug Designation, ODD, for the treatment of malignant glioma and provided additional business highlights. "The IND clearance for TNG462 is a critical step toward addressing the significant unmet need of patients with MTAP-deleted solid tumors," said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. "By advancing both TNG908 and TNG462 into the clinic, we not only increase our strategic optionality to develop and potentially commercialize a PRMT5 inhibitor, but also maximize the opportunity to help patients with MTAP-deleted cancers given the breadth of potential indications. We look forward to results from these trials to optimize our development plans for these programs."

07:08 EST Small Pharma reports topline results from Phase IIa trial of SPL026 - Small Pharma announces that SPL026, intravenous N,N-Dimethyltryptamine , with supportive therapy for the treatment of Major Depressive Disorder met the primary endpoint in its Phase IIa clinical trial, demonstrating a statistically significant and clinically relevant reduction in depressive symptoms at two-weeks post-dose, as compared to placebo. Further analysis of key secondary endpoints demonstrated a rapid and durable antidepressant effect to 12-weeks. The trial investigated the efficacy and safety of intravenous SPL026, with supportive therapy, in 34 patients with moderate/severe MDD. Participants who entered the trial on pharmacological antidepressant medication were withdrawn from their treatment prior to dosing. Patients were dosed with a short IV infusion of 21.5mg of SPL026, resulting in a 20 to 30-minute psychedelic experience. The dose was selected as a result of data analysis from the Company's Phase I study confirming that it was well tolerated and delivered a consistent psychedelic experience in healthy volunteers. The two-staged Phase IIa study included a blinded, randomized, placebo-controlled phase, where the primary endpoint was to assess the efficacy of a single dose of SPL026 with supportive therapy versus placebo with therapy at two-weeks post-dose. All study participants were subsequently enrolled into an open-label phase of the study where they received a single dose of SPL026 with supportive therapy, and were followed-up for a further 12-weeks in study**. This open-label trial design enabled the assessment of durability of antidepressant effect, as well as the comparative efficacy and safety of a one versus two dose regimen of SPL026. Efficacy was assessed using the Montgomery-Asberg Depression Rating scale to measure any potential change in patients' depression from baseline. MADRS was assessed by independent raters who were not present at dosing and were blinded to the overall treatment. The Phase IIa study met the primary endpoint demonstrating a statistically significant and clinically relevant reduction in depressive symptoms two-weeks following a dose of SPL026 with supportive therapy, compared to placebo, demonstrating a -7.4 point difference in MADRS (p=0.02). Analysis of key secondary endpoints demonstrated a rapid onset of antidepressant effect one-week post-dose, with a statistically significant difference in MADRS score between the active and placebo groups of -10.8. Across the 12-week open-label phase, patients who received at least one active dose of SPL026 with supportive therapy reported a durable improvement in depression symptoms. No apparent difference in antidepressant effect was observed between a one and two dose regimen of SPL026. The total mean reduction in MADRS from baseline after a single dose of SPL026 was -15.4 at 12-weeks.

07:05 EST Uranium Energy receives $17.85M from DOE - Uranium Energy announced it has received $17.85M from the U.S. Department of Energy, or DOE, for supplying 300,000 pounds of U.S. origin uranium concentrates at $59.50/lb. to the DOE - National Nuclear Security Administration, or NNSA, under the contract awarded to the company announced on December 20, 2022. The award was in response to the NNSA's Request for Proposals to establish its strategic national Uranium Reserve program.

07:04 EST Nasdaq sees 2023 non-GAAP tax rate 24%-26% - The company is initiating its 2023 non-GAAP operating expense guidance to a range of $1,770 to $1,850 million. Nasdaq expects its 2023 non-GAAP tax rate to be in the range of 24% to 26%.

07:03 EST Penske Automotive increases quarterly dividend by 7% to 61c per share - Penske Automotive announced that its board of directors has increased the company's quarterly dividend by 4c per share, or 7%, to 61c per share. "Based on the strength of the Company's diversified business model and our continued strong cash flow, we are pleased to provide our shareholders with an increase in the cash dividend," said Penske Automotive Group President, Robert Kurnick. The dividend is payable March 1 to shareholders of record as of February 10.

06:55 EST MAG reports Q4 production at Juanicipio 165,786 tonnes of mineralized material - MAG Silver reports production from the Juanicipio Project for the Q4. As reported to MAG by the project operator Fresnillo, 165,786 tonnes of mineralized material from both underground development and initial stopes were processed during the three months ended December 31, 2022 at an average silver head grade of 415 grams per tonne, or g/t. For the year ended December 31, 2022, a total of 646,148 tonnes of mineralized material were processed at an average silver head grade of 520 g/t. Total Juanicipio production for Q4 and 2022, based on provisional estimates before offtake agreement adjustments, totaled 1,861 koz of silver and 5,380 gold ounces, and 9,250 koz of silver and 22,253 gold ounces, respectively. The associated lead and zinc production will be reported with MAG Silver's year end filings. The Juanicipio beneficiation plant, which was recently energized with the connection to the national power grid, has commenced commissioning and full-scale ramp up of milling activities. Juanicipios property belongs to Fresnillo, 56%, and MAG, 44%.

06:53 EST RPC, Inc. increases quarterly cash dividend to 4c per share - RPC, Inc. announced that its board of directors declared a 2c per share increase to the regular quarterly cash dividend from 2c per share to 4c per share payable March 10 to common stockholders of record at the close of business on February 10.

06:50 EST U.S. Bancorp CEO says 'solid net interest income' in 2022 - Andy Cecere, Chairman, President and CEO, U.S. Bancorp said, ""Full year results, as adjusted, were highlighted by strong pre-provision earnings growth, driven by solid net interest income, wider net interest margin, and positive operating leverage over 230 basis points. On December 1 we completed the acquisition of MUFG Union Bank, which meaningfully increased our market share in California by adding one million consumer, 700 commercial, and 190,000 business banking customers. We expect the transaction to be 8 to 9% accretive to 2023 EPS as the benefits of increased scale, cost synergies, and Union Bank's core deposit franchise are realized. Credit quality remains strong as we prudently manage with a through-the-cycle view and we continue to maintain healthy capital and liquidity levels given the uncertain economic environment. As of December 31, our common equity tier 1 ratio was 8.4%. I want to thank our dedicated U.S. Bank employees as we continue to work towards a successful systems integration and account conversion of Union Bank customers expected in the second quarter of 2023."

06:38 EST BrightView acquires Smith's Tree Care, terms not disclosed - BrightView announced the acquisition of Smith's Tree Care, a tree care service provider, based in Newport News, Va. Terms of the transaction were not disclosed.

06:35 EST MarketAxess sees FY23 CapEx $52M-$58M - Total expenses are expected to be in the range of $418M-$446M. Based on the midpoint of the stated guidance range, operating expenses are expected to increase by approximately 10%. This 2023 guidance is based on foreign exchange rates as of December 31, 2022. The company's overall effective tax rate is expected to be between 25.0% and 26.0%.

06:11 EST Canoo signs exclusive sale, service and distribution agreement with GCC Olayan - Canoo signed an exclusive agreement with GCC Olayan, a multi-national subsidiary of Olayan Saudi Holding Company, or OSHCO, for sale, service, and distribution of Canoo fleet solutions in Saudi Arabia. GCC Olayan has been a distributor of brands in Saudi Arabia for more than 75 years and is the founding company of the global Olayan Group. The first phase of the agreement is for the sale, distribution, service maintenance, and repair of Canoo vehicles. Additionally, Canoo and GCC Olayan will also work to develop a joint venture to launch a digital vehicle ecosystem for service maintenance repair, local assembly, and eventually manufacturing.

06:08 EST Graphex and Gratomic sign LOI to negotiate terms of a Joint Venture - Graphex Group and its U.S. subsidiary, Graphex Technologies announced they have entered into a non-binding Letter of Intent, or LOI, with Gratomic, a graphite company based in Toronto, Ontario. The intent of the LOI is to combine Gratomic's raw material supply capabilities with Graphex's proven downstream processing expertise to solve an industry wide supply-demand gap by delivering an end-to-end supply of graphite from mine to battery with facilities to be located in North America. Pursuant to the LOI, Graphex and Gratomic intend to negotiate the terms of a Joint Venture, including management and ownership structures, to jointly produce coated spherical graphite anode material for the EV/battery market. Graphex will license and/or contribute its technology and expertise to the Joint Venture and Gratomic will provide security of raw material supply. It is contemplated that Graphex will provide all the technology, plans and expertise for building and operating the plant.

06:04 EST Immuron responds to FDA regarding clinical hold of Campylobacter and ETEC trial - Immuron announces that a response letter has been submitted to the FDA. Immuron has previously reported feedback was received from the FDA following a review of the Investigational New Drug, or IND, application of a new oral therapeutic targeting Campylobacter and ETEC developed in collaboration with Immuron. The FDA informed the NMRC that based on its review of the nonclinical data, the agency was placing a clinical hold on the clinical trials of the new oral therapeutic under the IND application. The Sponsor Investigator and Principal Investigator from Johns Hopkins University Bloomberg School of Public Health and personnel from the Naval Medical Research Center and Immuron participated in a virtual meeting with the FDA on the 2 December 2022 to discuss the clinical hold and advise on a path forward to address the safety concerns and supporting data associated with this new product. The FDA provided written guidance to the NMRC following the meeting on the 20 December 2022. NMRC, JHU and Immuron have now addressed the specific concerns of the FDA clinical hold and a response letter has been submitted. The agency will provide feedback on the clinical hold in 30 calendar days from receipt of the NMRC information package.

05:50 EST Microsoft cloud outage hits users around the globe - Microsoft is investigating a "potential networking issue" impacting Teams, Azure, Outlook, and more, taking them down in India, Japan, the U.K, and elsewhere, Azure said on its status page. Reference Link

05:14 EST Innate Pharma announces HSR clearance for Sanofi collaboration expansion - Innate Pharma (IPHA) announced the expiration of the waiting period under the Hart-Scott-Rodino, or HSR, Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi (SNY). The licensing agreement is now effective. As announced on December 19, 2022, Sanofi is licensing a Natural Killer, or NK, cell engager program targeting B7H3 from Innate's Anket platform. Sanofi will also have the option to add up to two additional Anket targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Under the terms of the agreement, Innate will receive EUR 25M upfront payment and up to EUR 1.35B total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.